Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-LAG-3/PD-1 bispecific antibody INCA32459

A human immunoglobulin G1 (IgG1) Fc-silenced bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; programmed death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3/PD-1 bispecific antibody INCA32459 targets and binds to both PD-1 and LAG-3 expressed on T cells and inhibits PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation. This may lead to cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-LAG3/PD1 bispecific antibody INCA32459
anti-PD-1/anti-LAG-3 bispecific antibody INCA32459
anti-PD-1/LAG-3 bispecific antibody INCA32459
PD-1 x LAG-3 bispecific antibody INCA32459
Code name:INCA 32459
INCA-32459
INCA32459
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search